Allarity Therapeutics Inc. (ALLR)
NASDAQ (CM) NASDAQ (CM) Primary 
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.
ALLR STOCK ALERT: Levi & Korsinsky Notifies Allarity Therapeutics, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Allarity Therapeutics, Inc. (ALLR)
NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
ALLR STOCK ALERT: Levi & Korsinsky Notifies Allarity Therapeutics, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.
Shareholders that lost money on Allarity Therapeutics, Inc.(ALLR) should contact Levi & Korsinsky about Securities Fraud Investigation - ALLR
NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
ALLR ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Allarity Therapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / July 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
Allarity Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ALLR
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
Shareholders that lost money on Allarity Therapeutics, Inc. (ALLR) should contact Levi & Korsinsky about Securities Fraud Investigation - ALLR
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
ALLR Investors Can Participate In The Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Did Allarity Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALLR
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.
